Edition:
United States

Profile: Albireo Pharma Inc (ALBO.OQ)

ALBO.OQ on NASDAQ Stock Exchange Capital Market

31.05USD
18 Apr 2019
Change (% chg)

$0.30 (+0.98%)
Prev Close
$30.75
Open
$30.65
Day's High
$31.05
Day's Low
$30.45
Volume
6,587
Avg. Vol
12,534
52-wk High
$37.67
52-wk Low
$19.43

Albireo Pharma, Inc., formerly Biodel Inc., incorporated on December 8, 2003, is a specialty biopharmaceutical company. The Company is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. Other products in the Company's pipeline include Elobixibat, A3384 and Bile Acid Modulators.

A4250

A4250 is a potent and selective inhibitor of intracapsular brown adipose tissue (IBAT) that is designed to reduce bile acid reabsorption from the small intestine to the liver, leading to reduced levels of bile acids in the serum and liver and increased excretion of bile acids via the colon. A4250 is being evaluated in a Phase II clinical trial in children with chronic cholestasis. In addition to PFIC and subject to obtaining additional capital, the Company focuses on conducting clinical development of A4250 as a treatment for other pediatric cholestatic liver diseases and disorders.

Elobixibat

Elobixibat is indicated for the treatment of chronic constipation. Elobixibat has completed its Phase III clinical trials. Elobixibat is also an IBAT inhibitor. By inhibiting reabsorption of bile acids from the small intestine to the liver, Elobixibat manages the flow of bile acid to the colon.

A3384

A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. The Company is developing A3384 as a treatment for bile acid malabsorption (BAM). The Company has completed a Phase II clinical trial of a prior formulation of A3384 in BAM and is in the late-stages of a subsequent pharmaceutical development program designed to identify an optimized formulation of A3384 capable of delivering cholestyramine to the colon.

Company Address

Albireo Pharma Inc

10 Post Office Square, Suite 502
BOSTON   MA   02109
P: +1857.4154774
F: +1302.6365454

Company Web Links